Patents Assigned to The Board of Regents of the University of Texas System
  • Patent number: 11519857
    Abstract: Disclosed herein are nanostructured plasmonic materials. The nanostructured plasmonic materials can include a first nanostructured layer comprising: a first layer of a first plasmonic material permeated by a first plurality of spaced-apart holes, wherein the first plurality of spaced apart holes comprise a first array; and a second nanostructured layer comprising a second layer of a second plasmonic material permeated by a second plurality of spaced-apart holes, wherein the second plurality of spaced apart holes comprise a second array; wherein the second nanostructured layer is located proximate the first nanostructured layer; and wherein the first principle axis of the first array is rotated at a rotation angle compared to the first principle axis of the second array.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 6, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Yuebing Zheng, Zilong Wu
  • Patent number: 11522725
    Abstract: A method, system and computer program product for reducing the amount of helper data that needs to be stored using two innovative techniques. The first technique uses bit-error-rate (BER)-aware lossy compression. By treating a fraction of reliable bits as unreliable, it effectively reduces the size of the reliability mask. With the view of practical costs of production-time error characterization, the second technique enables economically feasible across-temperature per-bit BER evaluation for use in a number of fuzzy extractor optimizations based on bit-selection to reduce overall BER (with or without subsequent compression) using room-temperature only production-time characterization. The technique is based on stochastic concentration theory and allows efficiently forming confidence intervals for average across-temperature BER of a selected set of bits.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: December 6, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Orshansky, Ye Wang
  • Patent number: 11517877
    Abstract: Disclosed are air-stable small-molecule adsorbents trimeric [Cu—Br]3 and [Cu—H]3 that undergo a reversible solid-state molecular rearrangements to [Cu—Br.(alkene)]2 and [Cu—H.(alkene)]2 dimers. The reversible solid-state rearrangement allows one to break adsorbent design trade-offs and achieve low heat of adsorption while retaining high selectivity and uptake.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: December 6, 2022
    Assignees: Board of Regents, The University of Texas System, University of Canterbury
    Inventors: Rasika Dias, Matthew Greig Cowan, Devaborniny Parasar
  • Patent number: 11517633
    Abstract: Described are methods for preparing radionuclides, such as radionuclides having a high specific activity. The disclosed methods include irradiating target nuclide materials, in solution, with a neutron source. The radionuclides can be separated from the target nuclide material by providing a solid carbon nanostructured material, as a suspension of solids, proximal to the target nuclide material in solution and using the recoil to drive adsorption of the radionuclide onto the solid carbon nanostructured material to transfer the radionuclides from the liquid phase (in solution) to the solid phase (adsorbed to the suspended solid carbon nanostructured material). One or more surfactants can be incorporated into the solution to facilitate formation of a stable suspension of the solid carbon nanostructured material.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: December 6, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: William S Charlton, Donald D. Nolting, Adam J. Samia, Joseph Lapka
  • Patent number: 11518800
    Abstract: Antibodies exhibiting a specific genetically modified signature associated with certain diseases of the central nervous system, like multiple sclerosis (MS) and clinically isolated syndrome have been identified. These antibodies recognize and bind with certain tissues in the brain and central nervous system and thus are useful as therapeutics, in the production of animal disease models, targets for therapies and as part of assays of the central nervous system.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: December 6, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventor: Nancy Monson
  • Patent number: 11522487
    Abstract: Disclosed are various embodiments for optimizing energy management. A quantity of renewable power that will be generated by renewable energy generation sources can be forecasted. The energy demand for a building or a cluster of buildings can be forecasted. A pricing model for buying energy from a grid can be determined. A quantity of energy to import from the grid or export to the grid can be scheduled based on the quantity of renewable energy forecasted and the state of charge or health of battery energy storage system, current and future operations of building HVAC, lighting and plug loads system, the forecasted energy demand for the building, and the pricing of the energy from the grid.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: December 6, 2022
    Assignee: BOARDS OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Bing Dong, Zhaoxuan Li, Jeff Qiang Xu
  • Publication number: 20220380767
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 1, 2022
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • Publication number: 20220380765
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a p53 mutation by administering an inhibitor of nonsense mediated decay. The patient may be further administered an inhibitor of mRNA splicing and/or an inhibitor of MDM.
    Type: Application
    Filed: November 2, 2020
    Publication date: December 1, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: John V. HEYMACH, Jayanthi GUDIKOTE, Tina CASCONE
  • Publication number: 20220380429
    Abstract: Provided herein are polypeptides comprising membrane-anchored IL-12. Also provided herein are T cells expressing the membrane-anchored IL-12. Further, methods of treating cancer comprising administering T cells expressing membrane-anchored IL-12 are provided herein. Also provided are combination treatments comprising T cells expressing membrane-anchored IL-12 and T cell chemoattractant-inducing chemokines. In addition, methods are provided for activating T cells to express NKG2D and methods of their use in the treatment of cancer.
    Type: Application
    Filed: July 21, 2022
    Publication date: December 1, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Shulin LI, Jiemiao HU, Xueqing XIA
  • Publication number: 20220380534
    Abstract: The present disclosure relates to degradable polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and have backbones which are capable of undergoing degradation in vivo. In some aspects, the disclosure also provides methods of using these degradable polymers for the delivery of a drug.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 1, 2022
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Jinming GAO, Xu WANG, Houliang TANG, Wei LI, Jonathan WILHELM, Baran SUMER
  • Publication number: 20220380766
    Abstract: Provided herein are DNA aptamers targeting AXL receptor kinase. The DNA aptamers may comprise a thiophosphate backbone and be chemically modified. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: December 1, 2022
    Applicants: Board of Regents, The University of Texas System, Consiglio Nazionale delle Ricerche
    Inventors: Gabriel LOPEZ-BERESTEIN, Paola AMERO, Cristian RODRIGUEZ-AGUAYO, Rahul MITRA, Anil K. SOOD, Vittorio DE FRANCISCIS, David VOLK, Lokesh Ganesh L. RAO
  • Patent number: 11510615
    Abstract: Methods, apparatuses, systems, and implementations for inductive heating of a foreign metallic implant are disclosed. A foreign metallic implant may be heated via AMF pulses to ensure that the surface of the foreign metallic implant heats in a uniform manner. As the surface temperature of the foreign metallic implant rises, acoustic signatures may be detected by acoustic sensors that may indicate that tissue may be heating to an undesirable level approaching a boiling point. Once these acoustic signatures are detected, the AMF pulses may be shut off for a time period to allow the surface temperature of the implant to cool before applying additional AMF pulses. In this manner, the surface temperature of a foreign metallic implant may be uniformly heated to a temperature adequate to treat bacterial biofilm buildup on the surface of the foreign metallic implant without damaging surrounding tissue.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: November 29, 2022
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Rajiv Chopra, David Greenberg, Yonatan Chatzinoff
  • Patent number: 11510880
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: November 29, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Patent number: 11512589
    Abstract: A device for measuring strain on the exterior of a pipe includes a body comprising a top portion and a bottom portion; one or more elastically deformable members coupled between the top portion and the bottom portion, wherein each of the one or more elastically deformable members have an outer contact surface and an inner non-contact surface. One or more sensors are disposed on the inner non-contact surface of one or more of the elastically deformable members. The sensors, during use, provide data that can be used to determine changes in strain on the exterior of the pipe. In another embodiment, one or more sensors are embedded in, or attached to, a casing disposed in a wellbore. In an embodiment, a method includes pressurizing or depressurizing the wellbore with a fluid and measuring the strain induced in the casing (or in an open wellbore) in response to this change in wellbore pressure.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: November 29, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Rodney Thompson Russell, Mukul Sharma
  • Patent number: 11512312
    Abstract: Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 29, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Venkateswara V. Mootha, David R. Corey, Jiaxin Hu
  • Patent number: 11516658
    Abstract: The techniques described herein may provide an efficient and secure two-party distributed signing protocol for the identity-based signature scheme described in the IEEE P1363 standard. For example, in an embodiment, a method may comprise generating a distributed cryptographic key at a key generation center and a first other device and a second other device and generating a distributed cryptographic signature at the first other device using the second other device.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: November 29, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Debiao He, Kim Kwang Choo
  • Patent number: 11512141
    Abstract: Provided herein are anti-FGL2 monoclonal antibodies. Further provided herein are methods to reverse suppressive immune mechanisms, such as for the treatment of cancer or infectious diseases.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: November 29, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Shulin Li, Jun Yan, Jiemiao Hu, Xueqing Xia, Qingnan Zhao
  • Patent number: 11514301
    Abstract: The present disclosure provides a domain wall magnetic tunnel junction device. Integration of input spikes pushes a domain wall within a ferromagnetic track toward a magnetic tunnel junction (MTJ). An energy gradient within the track pushes the domain wall away from the MTJ by leaking accumulated energy from the input spikes. If the integrated input spikes exceed the energy leak of the gradient within a specified time period, the domain wall reaches the MTJ and reverses its resistance, producing an output spike. The leaking energy gradient can be created by a magnetic field, a trapezoidal shape of the ferromagnetic track, or nonuniform material properties in the ferromagnetic track.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: November 29, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joseph S. Friedman, Wesley H. Brigner, Naimul Hassan, Xuan Hu
  • Publication number: 20220370471
    Abstract: Hippocampal lesions, including synaptic failure, are a defining pathology of Alzheimer's disease (AD). However, the molecular mechanisms that underlie hippocampal synaptic injury in this neurodegenerative disorder have yet not been fully elucidated. In Current therapeutic efforts for the treatment of AD are not effective in correcting hippocampal synaptic deficits. It is disclosed that the interaction with amyloid beta (A?) induces dysfunction of growth hormone secretagogue receptor 1a (GHSR1?; ghrelin receptor), leading to suppressed GHSR1? regulation of hippocampal dopamine receptor D1 (DRD1) in AD hippocampi. The modulation of DRD1 by GHSR1? impacts hippocampal synaptic plasticity. The simultaneous application of a selective GHSR1? agonist and a selective DRD1 agonist mitigates A?-induced hippocampal synaptic injury and improves spatial memory in AD mouse models.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 24, 2022
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Heng Du
  • Publication number: 20220372092
    Abstract: Provided herein are tumor-antigen VCX/Y specific peptides. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. Immunogenic compositions comprising VCX/Y-specific peptides are also provided. In a further embodiment, there is provided a protein complex comprising a peptide according to any of the embodiments and aspects described above in complex with HLA. In some aspects, the HLA is a HLA-A11, HLA-DR, or HLA-DQ.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 24, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Cassian YEE, Ke PAN